An Evaluation of Generic and Disease-Specific Patient-Reported Outcome Measures to Assess the Impact of Percentage of Scalp Hair Loss on Health-Related Quality of Life in a European Population
January 2025
in “
JEADV Clinical Practice
”
TLDR Disease-specific tools better assess alopecia areata's impact on quality of life.
The study assessed the impact of scalp hair loss on health-related quality of life in 435 European patients with alopecia areata using both generic (EQ-5D-5L) and disease-specific (AAPPO) patient-reported outcome measures. It found that the AAPPO, which focuses on emotional symptoms and activity limitations, provides a more comprehensive assessment of the disease's impact compared to the EQ-5D-5L, which may not fully capture the specific impacts of alopecia areata. The study highlights the importance of using disease-specific instruments to better understand the multifactorial nature of alopecia areata and its effects on patients' lives. Limitations include the lack of independent validation of medical data and a non-generalizable sample.
